Shattuck Labs to Present Virtually at Cowen 4th Annual IO Next Summit

Rhea-AI Summary

Austin, TX and Durham, NC – November 6, 2020 – Shattuck Labs (NASDAQ: STTK), a clinical-stage biotechnology company focused on bi-functional fusion proteins for cancer and autoimmune disease treatment, announced participation in the Cowen 4th Annual IO Next Summit on November 13, 2020. CEO Taylor Schreiber and senior executives will join a fireside chat with analyst Marc Frahm. The presentation is scheduled for 2:15 p.m. EST and can be accessed via a webcast. Shattuck's innovative ARC® platform develops therapies inhibiting immune checkpoints while activating costimulatory pathways.

AUSTIN, TX and DURHAM, NC, Nov. 06, 2020 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) (NASDAQ: STTK), a clinical-stage biotechnology company pioneering the development of bi-functional fusion proteins as a new class of biologic medicine for the treatment of patients with cancer and autoimmune disease, today announced that Taylor Schreiber, M.D., Ph.D., Chief Executive Officer, and other senior executives will participate in the Cowen 4^th Annual IO Next Summit 2020 on November 13, 2020.

Conference Presentation Details
Conference: Cowen 4^th Annual IO Next Summit
Format: Fireside chat with covering analyst, Marc Frahm, Ph.D.
Date: November 13, 2020
Time: 2:15 p.m. EST
Webcast Link: Available Here

The live webcast of the fireside chat will be available on the Events & Presentations section of the Company’s website. A replay of the webcast will be archived for up to 90 days following the presentation date.

About Shattuck Labs, Inc.
Shattuck is a clinical-stage biotechnology company pioneering the development of bi-functional fusion proteins as a new class of biologic medicine for the treatment of patients with cancer and autoimmune disease. Compounds derived from Shattuck’s proprietary Agonist Redirected Checkpoint, ARC^®, platform simultaneously inhibit checkpoint molecules and activate costimulatory molecules within a single therapeutic. The company’s lead wholly owned program, SL-172154 (SIRPα-Fc-CD40L), which is designed to block the CD47 immune checkpoint and simultaneously agonize the CD40 pathway, is being evaluated in a Phase 1 trial. A second compound, SL-279252 (PD1-Fc-OX40L), is being evaluated in a Phase 1 trial in collaboration with Takeda Pharmaceuticals. Additionally, the company is advancing a proprietary Gamma Delta T Cell Engager, GADLEN™, platform, which is designed to bridge gamma delta T cells to tumor antigens for the treatment of patients with cancer. Shattuck has offices in both Austin, Texas and Durham, North Carolina. For more information, please visit: www.ShattuckLabs.com.

Investor Contact:
Conor Richardson
Director of Finance
Shattuck Labs, Inc.
InvestorRelations@shattucklabs.com

Media Contact:
Stephanie Ascher
Managing Director
Stern Investor Relations, Inc.
Stephanie.ascher@sternir.com

FAQ

What is the date of the Cowen 4th Annual IO Next Summit for Shattuck Labs?

The Cowen 4th Annual IO Next Summit for Shattuck Labs will take place on November 13, 2020.

Who will participate in the Cowen 4th Annual IO Next Summit?

CEO Taylor Schreiber and other senior executives from Shattuck Labs will participate in the Cowen 4th Annual IO Next Summit.

At what time will Shattuck Labs present at the conference?

Shattuck Labs' presentation at the Cowen 4th Annual IO Next Summit is scheduled for 2:15 p.m. EST.

How can I access the Shattuck Labs webcast for the presentation?

The webcast for Shattuck Labs' presentation can be accessed through their website under the Events & Presentations section.

What is the focus of Shattuck Labs' bi-functional fusion proteins?

Shattuck Labs' bi-functional fusion proteins focus on the treatment of cancer and autoimmune diseases.

What is the ticker symbol for Shattuck Labs?

The ticker symbol for Shattuck Labs is STTK.